BCO vs COGT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BCO · The Brink's$112.90 ▼ 0.76%
COGT · Cogent Biosciences$26.72 ▼ 3.70%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BCO +2.3%
- COGT -30.7%
Head to head
| Metric | BCO | COGT |
|---|---|---|
| Price | $112.90 | $26.72 |
| Change today | ▼ 0.76% | ▼ 3.70% |
| Market cap | $4.65B | $4.65B |
| Return, 3 months | +0.1% | -26.3% |
| Return, year to date | -2.6% | -24.8% |
| Return, 1 year | +2.9% | -27.3% |
| P/E (TTM) | 29.7 | – |
| P/B | 15.5 | 10.3 |
| P/E percentile vs own 5y | 65th | 20th |
| Dividend yield | 0.90% | – |
| Revenue growth (YoY, latest qtr) | +3.0% | – |
| Net profit growth (YoY) | -56.1% | -37.7% |
| Gross margin | 26.1% | – |
| Operating margin | 9.7% | – |
| Net margin | 2.9% | – |
| Return on equity | 56.0% | -126.2% |
| Analyst target vs. price | +19.6% | +107.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 53 | 36 |
| 30-day volatility | 39.4% | 58.3% |
| Max drawdown, 1 year | -31.9% | -37.6% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BCO is the largest of the group by market value.
- BCO has returned the most over the past year.
- BCO has been the calmest stock over the last 30 days.